Literature DB >> 7620113

Levels of vitamin K, immunoreactive prothrombin, des-gamma-carboxy prothrombin and gamma-glutamyl carboxylase activity in hepatocellular carcinoma tissue.

H Yamagata1, T Nakanishi, M Furukawa, H Okuda, H Obata.   

Abstract

To clarify the mechanism of production of des-gamma-carboxy (abnormal) prothrombin (DCP) by hepatocellular carcinoma (HCC), we measured the levels of vitamin K, DCP, immunoreactive prothrombin and the activity of gamma-glutamyl carboxylase in liver tissues from HCC patients and in the medium of cultured human hepatoma cells. There was no significant difference in vitamin K (K1, MK-4) contents between HCC and non-HCC cirrhotic liver tissues. The activity of gamma-glutamyl carboxylase per unit amount of endogenous microsomal prothrombin precursor was decreased in HCC tissue compared with non-HCC liver tissue (positive plasma DCP: 335 +/- 72 vs 372 +/- 67, negative plasma DCP: 370 +/- 84 vs 393 +/- 56 nmol/min per mg prothrombin precursor, P > 0.05), although the total incorporation of 14COOH into microsomal precursor protein was higher in the former. By contrast, levels of DCP and immunoreactive prothrombin in HCC tissue were greater (P < 0.05) than those in non-HCC cirrhotic liver tissue. Furthermore, production of large amounts of immunoreactive prothrombin was observed in human hepatoma cells huH-1 and huH-2, which produced large amounts of DCP. These results suggest that there was excessive synthesis of prothrombin precursors by human HCC tissue and hepatoma cell lines huH-1 and huH-2. Thus, excessive synthesis of prothrombin precursors seems to be the main mechanism of DCP production by HCC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620113     DOI: 10.1111/j.1440-1746.1995.tb01040.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  4 in total

Review 1.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

2.  Effect of sorafenib on des-γ-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line.

Authors:  Sachiko Ogasawara; Masamichi Nakayama; Jun Akiba; Hironori Kusano; Hirohisa Yano
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

3.  Vitamin K contents in liver tissue of hepatocellular carcinoma patients.

Authors:  T Miyakawa; Y Kajiwara; A Shirahata; K Okamoto; H Itoh; K Ohsato
Journal:  Jpn J Cancer Res       Date:  2000-01

4.  Gla-rich protein is a potential new vitamin K target in cancer: evidences for a direct GRP-mineral interaction.

Authors:  Carla S B Viegas; Marjolein Herfs; Marta S Rafael; José L Enriquez; Alexandra Teixeira; Inês M Luís; Cynthia M R van 't Hoofd; Alexandre João; Vera L Maria; Sofia Cavaco; Ana Ferreira; Manuel Serra; Elke Theuwissen; Cees Vermeer; Dina C Simes
Journal:  Biomed Res Int       Date:  2014-05-18       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.